Amneal Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

19.80$ +2.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Amneal Pharmaceuticals, Inc. (AMRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 796 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement AMRX
Line item	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	299	226	260	255	293	275	414	476	498	446	405	378	397	499	465	519	510	493	535	529	537	498	559	546	610	558	599	620	617	659	702	702	731	695	725	785	814	723	796	3,118
Cost of Revenue	122	116	136	120	142	131	235	276	304	363	299	324	287	315	320	386	343	302	323	330	370	323	359	351	394	379	379	388	392	421	452	433	468	440	438	511	517	402	462	1,892
Gross Profit	177	110	124	135	151	145	178	200	193	83	105	54	110	183	144	134	167	192	212	199	166	175	201	194	215	178	220	233	225	238	250	270	263	256	286	274	297	320	335	1,226
Research & Development	44	39	52	48	46	49	54	47	61	58	51	41	53	38	49	47	57	52	54	51	53	54	52	52	43	40	39	42	47	39	37	61	56	42	50	63	35	38	41	178
Selling, General & Administrative	31	27	27	27	27	25	53	78	71	84	67	64	152	78	81	83	85	85	86	91	89	99	99	99	106	102	106	113	97	113	116	119	94	118	124	138	146	187	149	620
Total Operating Expenses	101	52	79	75	73	74	107	125	132	142	118	105	133	126	133	131	147	146	145	170	155	151	399	150	179	144	140	157	211	249	154	181	187	156	175	274	183	177	189	823
Operating Income	92	43	45	79	79	64	-181	75	23	-94	-19	-112	-23	58	11	2.4	20	46	67	29	11	23	-199	44	36	34	80	76	14	-11	95	89	76	100	111	-0.1	115	143	146	403
Interest Expense	20	26	18	19	20	21	37	43	43	43	44	42	39	40	37	35	35	34	34	34	34	33	36	42	47	49	51	51	60	66	66	66	62	57	65	63	56	53	55	227
Pre-Tax Income	56	43	40	26	62	52	-263	23	-15	-133	-56	26	-57	13	-22	-22	-5.5	15	35	-2.0	-16	-9.9	-233	2.2	-7.7	-9.4	30	23	-83	-76	20	15	-15	37	52	-5.2	55	80	71	201
Income Tax Expense	1.6	1.0	1.9	-0.7	-0.1	0.4	-12	5.1	5.5	-8.4	-5.7	390	7.8	-108	2.2	0.1	1.5	0.4	2.6	4.0	4.1	-3.5	7.4	4.6	-1.8	0.7	0.0	-2.1	9.9	6.2	3.6	3.7	5.4	13	16	-23	5.7	2.2	1.4	-14
Net Income	54	42	37	27	62	52	-219	7.0	-8.8	-48	-17	-265	-32	115	-12	-9.0	-3.0	6.7	15	-4.2	-6.4	-2.2	-121	-2.7	-4.3	-6.9	12	9.7	-99	-92	6.0	-0.2	-31	12	22	2.4	35	62	58	157
EBITDA	102	53	45	72	115	85	-181	129	76	-41	38	122	36	111	73	72	89	104	125	93	79	81	-137	106	100	98	138	131	33	46	142	140	112	155	177	112	161	186	194	652

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings